These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. Malaquin N; Vancayseele A; Gilbert S; Antenor-Habazac L; Olivier MA; Ait Ali Brahem Z; Saad F; Delouya G; Rodier F Cells; 2020 Jul; 9(7):. PubMed ID: 32630281 [TBL] [Abstract][Full Text] [Related]
3. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
4. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467 [TBL] [Abstract][Full Text] [Related]
5. Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. Wu H; Sun C; Cao W; Teng Q; Ma X; Schiöth HB; Dong R; Zhang Q; Kong B Cancer Lett; 2024 Oct; 602():217192. PubMed ID: 39181433 [TBL] [Abstract][Full Text] [Related]
6. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899 [TBL] [Abstract][Full Text] [Related]
7. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. Bahar E; Kim JY; Kim DC; Kim HS; Yoon H Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140 [TBL] [Abstract][Full Text] [Related]
9. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128 [TBL] [Abstract][Full Text] [Related]
10. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306 [TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors: Synthetic lethality in the clinic. Lord CJ; Ashworth A Science; 2017 Mar; 355(6330):1152-1158. PubMed ID: 28302823 [TBL] [Abstract][Full Text] [Related]
12. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391 [TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. Li N; Wang Y; Deng W; Lin SH Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic applications of PARP inhibitors in ovarian cancer. Xie H; Wang W; Xia B; Jin W; Lou G Biomed Pharmacother; 2020 Jul; 127():110204. PubMed ID: 32422564 [TBL] [Abstract][Full Text] [Related]
15. Targeting the nucleotide salvage factor DNPH1 sensitizes Fugger K; Bajrami I; Silva Dos Santos M; Young SJ; Kunzelmann S; Kelly G; Hewitt G; Patel H; Goldstone R; Carell T; Boulton SJ; MacRae J; Taylor IA; West SC Science; 2021 Apr; 372(6538):156-165. PubMed ID: 33833118 [TBL] [Abstract][Full Text] [Related]
16. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
17. [PARP inhibitors - A better selection of patients]. Senglet M; Berthod G; Courtes MG; Anchisi S; Membrez V; Nay Fellay C Rev Med Suisse; 2023 May; 19(827):932-937. PubMed ID: 37195105 [TBL] [Abstract][Full Text] [Related]
18. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272 [TBL] [Abstract][Full Text] [Related]
19. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Lau CH; Seow KM; Chen KH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700 [TBL] [Abstract][Full Text] [Related]
20. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]